Axogen Inc. shares advanced to a 52-week high of $51.13 on Wednesday, extending a year-to-date gain of roughly 214%, as second-quarter 2026 revenue surpassed Wall Street projections.
The medical device company reported Q2 2026 revenue of $69.7 million, exceeding the $67.1 million consensus estimate compiled by Wall Street. Net loss narrowed to $1.5 million, or $0.03 per share, from a year-earlier loss of $2.3 million. Adjusted net income reached $7.3 million, or $0.12 per share, matching analyst expectations.
Revenue for the trailing twelve months grew approximately 24% year-over-year, while quarterly sales rose 23% compared with the same period in 2025. The company’s market capitalization stood at $2.73 billion as of the latest close.
Analysts at H.C. Wainwright raised their price target to $53 while maintaining a Buy rating. Citizens increased its target to $55, citing robust sales growth. Truist Securities initiated coverage with a Buy rating and set a $60 price target, emphasizing growth potential in the peripheral nerve repair market.
InvestingPro’s Fair Value analysis flagged the stock as potentially overvalued at current levels, placing it on the platform’s Most Overvalued list despite the recent rally. Axogen’s 52-week range spans from a low of $14.79 to the latest intraday peak of $51.13.
